RO27-3225 

RO27-3225 is potent and selective melanocortin 4 receptor (MC4R) agonist with an EC₅₀ of 1 nM and 8 nM for MC4R and MC1R, respectively. RO27-3225 shows 30-fold selectivity for MC4R over MC3R. RO27-3225 has neuroprotective and anti-inflammatory effects^[1][2][3].

EC50: 1 nM (Melanocortin 4 receptor (MC4R)), 8 nM (MC1R), 675 nM (MC3R) and 5779 nM (MC5R)^[1]

RO27-3225 (0.012-0.048 mg/kg; intravenous injection; Wistar rats) treatment reverses haemorrhagic shock, reduces multiple organ damage and improves survival. RO27-3225 could have a protective role against multiple organ failure following circulatory shock^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

784.91

C₃₉H₅₂N₁₂O₆

274682-89-2

{Butir}-His-{dPhe}-Arg-Trp-{Sar}-NH2

{Butir}-H-{dPhe}-RW-{Sar}-NH2

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Benoit SC, et al. A novel selective melanocortin-4 receptor agonist reduces food intake in rats and mice without producing aversive consequences. J Neurosci. 2000 May 1;20(9):3442-8.  [Content Brief]

  [2]. Giuliani D, et al. Selective melanocortin MC4 receptor agonists reverse haemorrhagic shock and prevent multiple organ damage. Br J Pharmacol. 2007 Mar;150(5):595-603.  [Content Brief]

  [3]. Zhang Y, et al. Effects of RO27-3225 on neurogenesis, PDGFRβ+ cells and neuroinflammation after cerebral infarction. Int Immunopharmacol. 2020 Feb 11;81:106281.  [Content Brief]